JP, none of what you mentioned is mutually exclusive to a turnaround. The list of pre-rev biotechs that have huge valuations or medium sized valuations, or tiny valuations is long. Almostt as long as the list of pre-rev bios that die.
We are priced for bankruptcy right now. There are many paths ahead that avoid bankruptcy that create "shareholder value" as the ole boy says simply because market prices us dead. Market has forgotten us.
I cannot tell you how we'll produce revenue because we probably won't (although share sales of AVDX may become revenue depending on the deal.) And I think, as long as you've been here, if you've avoided averaging down, you will never make your money back, which is why I don't understand why you're here, but bless your heart. I'm saying you can dish a little cash here with good risk reward based on how volatile the price is and the improving circumstances. Your concerns for the company's circumstances are obvious, but there is clearly a willingness by all parties to let the company right itself outside the courts, probably because it makes the most money sense to all parties. $ talks, and turnaround is only good option.
News 
Market Data 
Discover 
